Wednesday, August 31, 2011

ANA 598

Hep C.
Seems this company is just stringing along investors. All things considered, they will be delisted from NASDAQ soon. It really is a shame, excusing management for questionable decisions over the last 4 years. This could have been a nice co-treatment with SOC IFN.

Rev: CELG

Secondary Cancers.

More to come.

No comments: